Genome Editing: Fetal Origins of AML in Down Syndrome, With Drs. Adam Mead & Elvin Wagenblast

Contributing Editor Dr. Adam Mead has a conversation with Dr. Elvin Wagenblast about a study that used CRISPR/Cas9 genome editing of hematopoietic stem and progenitor cells from human fetal liver to induce transient abnormal myelopoiesis– and myeloid leukemia associated with Down syndrome–related mutations.

Show Notes

In this podcast, Contributing Editor Dr. Adam Mead has a conversation with Dr. Elvin Wagenblast. They discuss Dr. Mead’s Diffusion article from the September/October 2021 issue of The Hematologist, titled, "Genome Editing: The Fetal Origins of Acute Myeloid Leukemia in Down Syndrome." They discuss a study that used CRISPR/Cas9 genome editing of hematopoietic stem and progenitor cells from human fetal liver to induce transient abnormal myelopoiesis– and myeloid leukemia associated with Down syndrome–related mutations. You can access his Diffusion article online at https://ashpublications.org/thehematologist/article/doi/10.1182/hem.V18.5.202159/476568/Genome-Editing-the-Fetal-Origins-of-Acute-Myeloid.
Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/

What is The Hematologist?

The Hematologist is the member newsletter of American Society of Hematology (ASH). It is designed for the broad constituency of ASH, all working toward the ultimate goal of conquering blood diseases. The Hematologist updates readers about important developments in the field of hematology and highlights what ASH is doing for its members.